A cocktail drug of two antibodies “can almost completely block establishment” of the novel coronavirus in monkeys and hamsters, according to a prepublication copy of a study on the therapy.

REGN-COV2, developed by Regeneron Pharmaceuticals, “can greatly reduce virus load in lower and upper airway” when administered either as a preventive measure or treatment after infection, according to the study by a team from Regeneron, Southwest National Primate Research Center/Texas Biomedical Research Institute and science research company BIOQUAL.

The study was published on BioRxiv, an open access repository for biological research that has yet to be peer reviewed.

Read more at NEWSMAX.